DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, triple-negative breast cancer emerging drugs, market share of ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how positive Phase III results for Emrelis may position AbbVie as a key player in MET-high non-small cell lung cancer, ...

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

A deal with US WorldMeds includes the FDA-approved TCR therapy Tecelra and two clinical-stage cancer medicines.

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

Be hugged by an artificial 'muscle' in Japanese 'well-down' popup which involves relaxing into your natural self ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...